BCL2 and glioblastoma: Similarly, the survival of GBM-bearing mice treated with the senolytic drug ABT263 (Navitoclax, an inhibitor of the anti-apoptotic proteins BCL2 and BCL-xL13) increased significantly compared with control mice (WT+vhc) (Fig. 2b and d).